<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33602">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084719</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT02084719</nct_id>
  </id_info>
  <brief_title>Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rapid tests are increasingly used in medical practice, notably to screen for HIV.  Their use
      has been associated with a faster linkage to care and lower rates of loss to follow up.
      Rapid tests are also well accepted by patients and clinicians.

      No rapid test is currently approved in Canada for screening of hepatitis C.  Hepatitis C
      diagnosis is done through based on blood testing and the screening algorithm may require up
      to 3 visits to clarify the hepatitis C status.

      The Oraquick HCV test is a rapid test done on blood or saliva that can replace the first
      step of the regular screening algorithm.  With this test the initial screening and the
      confirmation test can be done in one visit.

      The primary endpoint of this pilot-project is to evaluate clinical characteristics of
      Oracquick HCV (sensitivity, specificity, positive and negative predictive values) and to
      compare them to those of the standard screening algorithm in a population of active or
      ex-users of injected drugs.  The project also intend to evaluate if the rapid test can
      reduce the rates of loss to follow up and increase the linkage to hepatitis C specialized
      care.  This last endpoint will be evaluated through phone call follow up 6 months after the
      screening.

      One hundred and fifty patients will be included.  Half will be tested with the standard
      algorithm and the Oraquick HCV test (group A) and half will be tested only with the standard
      algorithm.

      Results of group A will be used to determine the clinical characteristics of Oraquick HCV.
      Results of groups A and B will be used to evaluate rates of loss to follow up, costs avoided
      by the use of the rapid test and linkage to care of infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Proportion of patients for whom Oraquick HCV Antibody Test accurately diagnosed anti-HCV status</measure>
    <time_frame>Patients will be followed for an expected average of 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oraquick HCV Antibody test will be compared to a composite goldstandard:
If both the Oraquick test and the standard test are negative, the results will be considered as a true negative.
If both the Oraquick test and the standard test are positive, the results will be considered as a true positive.
If the tests are discordant, HCV RNA testing will be performed.  If HCV RNA is positive, the result of the test who predicted the positive result will be a true positive and the result of the other test will be a false negative.  If the HCV RNA is negative, the result of the standard test will be considered as the true value (either positive or negative).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loss to follow up</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients not completing the screening procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to care</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of infected patients initiating a follow up with an hepatitis C specialized provider</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoided costs</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Costs that could have been avoided by the use of the rapid test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>15 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients and provider satisfaction about the test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Active or Ex-injection Drug Users</condition>
  <condition>Indication of Hepatitis C Screening</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be tested only with the standard algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oraquick HCV Rapid Antibody Test</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard algorithm</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication of hepatitis C screening

          -  Active or ex-injection drug user

        Exclusion Criteria:

          -  Known hepatitis C infection

          -  Unknown HIV status and patient refusing to HIV testing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Martel-Laferrière, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de l'Université de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie Martel-Laferrière, MD</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>24720</phone_ext>
    <email>valerie.martel-laferriere.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Casavant</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>24720</phone_ext>
    <email>claire.casavant.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 2W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Martel-Laferrière, MD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>24720</phone_ext>
      <email>valerie.martel-laferriere.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Claire Casavant</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>24720</phone_ext>
      <email>claire.casavant.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Valérie Martel-Laferrière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Valérie Martel-Laferrière</investigator_full_name>
    <investigator_title>MD, MS, FRCPC</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
